TGFB1 and aortic aneurysm: Therefore, inhibiting TGF-β signaling to less than physiological levels results in adverse outcomes because it maintains homeostasis in the aortic wall, providing insight for the development of therapeutic agents to limit excessive TGF-β signaling in aortic aneurysms.